Recent advances in vitamin D implications in chronic respiratory diseases

Respir Res. 2022 Sep 19;23(1):252. doi: 10.1186/s12931-022-02147-x.

Abstract

Chronic airway inflammatory and infectious respiratory diseases are the most common medical respiratory conditions, associated with significant morbidity and mortality. Vitamin D (1,25(OH)2D3) deficiency has been shown to be highly prevalent in patients with chronic airway inflammatory and infectious diseases, correlated with increased disease severity. It has been established that vitamin D modulates ongoing abnormal immune responses in chronic respiratory diseases and is shown to restrict bacterial and viral colonization into the lungs. On the contrary, other studies revealed controversy findings regarding vitamin D efficacy in respiratory diseases. This review aims to update the current evidence regarding the role of vitamin D in airway inflammation and in various respiratory diseases. A comprehensive search of the last five years of literature was conducted using MEDLINE and non-MEDLINE PubMed databases, Ovid MEDLINE, SCOPUS-Elsevier, and data from in vitro and in vivo experiments, including clinical studies. This review highlights the importance of understanding the full range of implications that vitamin D may have on lung inflammation, infection, and disease severity in the context of chronic respiratory diseases.

Keywords: Airway infections; Airway inflammation; Immunomodulator; Respiratory diseases; Vitamin D (1,25(OH)2D3).

Publication types

  • Review

MeSH terms

  • Humans
  • Lung
  • Respiration Disorders*
  • Respiratory Tract Diseases*
  • Vitamin D / therapeutic use
  • Vitamin D Deficiency* / diagnosis
  • Vitamin D Deficiency* / drug therapy
  • Vitamin D Deficiency* / epidemiology

Substances

  • Vitamin D